Physician profile
Jordan Hyde
NPI 1992367056
$6,768.44
in general payments reported to CMS, 2019-2025
17 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $1,163 · 2023: $1,543 · 2024: $2,664 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,973 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,972.87 |
| Education | $163.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,909.65 | 2021-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $842.83 | 2021-2024 | Tremfya |
| Abbvie INC. | $822.10 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $431.50 | 2021-2024 | Dupixent |
| Ucb, INC. | $385.29 | 2022-2025 | Bimzelx |
| Genzyme Corporation | $361.40 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $299.54 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $296.46 | 2022-2024 | |
| Leo Pharma INC. | $272.75 | 2023-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $235.25 | 2024 | |
| Lilly USA, LLC | $214.78 | 2024 | Olumiant, Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $172.18 | 2025 | Nemluvio |
| Dermavant Sciences, INC. | $135.00 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $133.21 | 2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.69 | 2024 | Spevigo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $89.66 | 2025 | Spinosad, Natroba |
| Helsinn Therapeutics (U.S.), INC. | $42.15 | 2022-2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Hyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.